Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

NCT05874401 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: Trilaciclib
DRUG: Placebo
DRUG: Topotecan

Sponsor

Pharmacosmos A/S